Live Feeds
● LIVE Updated 1h ago · 23 sources tracked

FDA approves landmark pancreatic cancer drug that’s shown to improve survival

The FDA approved Rasonque (daraxonrasib), a daily oral RAS inhibitor, for adults with advanced pancreatic cancer. Developed by RevMed, the medication blocks a protein that drives tumor growth. Clinical data indicates the drug can nearly double patient survival rates for one of the deadliest cancer forms. Patients including former UF President Sasse and a stage 4 patient in Maine have credited the pill with extending their lives.

RSS Source map (23)

What changed

Medical reports confirm Rasonque is a RAS inhibitor tested in a global clinical trial.

Live updates

  1. FDA Approves Rasonque Pill for Advanced Pancreatic Cancer

    The FDA approved Rasonque (daraxonrasib), a daily oral RAS inhibitor, for adults with advanced pancreatic cancer. Developed by RevMed, the medication blocks a protein that drives tumor growth. Clinical data indicates the drug can nearly double patient survival rates for one of the deadliest cancer forms. Patients including former UF President Sasse and a stage 4 patient in Maine have credited the pill with extending their lives.

    Why it matters

    Metastatic pancreatic cancer has historically offered patients limited treatment options and short survival windows. This approval introduces the first pill specifically designed to extend survival in these cases.

    What is confirmed

    • The FDA approved Rasonque for adults with advanced pancreatic cancer.
    • Rasonque is a daily oral pill.
    • The drug functions as a RAS inhibitor.

    Still unconfirmed

    • Rasonque can nearly double patient survival rates.
    • Former UF President Sasse and a patient in Maine credit the drug with extending their lives.

    What to watch next

    • Long-term survival data from the global clinical trial.
    • Insurance coverage and accessibility updates for Rasonque.
    Sources used for this update (4)
    1. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
    2. apnews.com — Live updates: Iran war reaches its six-month mark as Trump turns focus to increasing economic pressure
    3. www.gastroenterologyadvisor.com — FDA Approves First Pill to Extend Survival In Advanced Pancreatic Cancer
    4. www.coloradopolitics.com — House will vote to denounce socialism
    confidence 90%

  2. FDA Approves RASONQUE for Advanced Pancreatic Cancer

    The FDA approved RASONQUE (daraxonrasib) on Wednesday to treat advanced pancreatic cancer. The once-daily pill blocks a protein that drives tumor growth and has shown the ability to nearly double patient survival rates. The drug is developed by RevMed and targets one of the deadliest forms of cancer. Early reports include a patient in Maine with stage 4 cancer and former UF President Sasse, who both credit the medication with extending their lives.

    Why it matters

    Pancreatic cancer is notoriously difficult to treat and often has low survival rates. This approval introduces a targeted approach to managing the disease. The drug's success may position RevMed as a major player in oncology.

    What is confirmed

    • The FDA approved RASONQUE (daraxonrasib) on Wednesday for advanced pancreatic cancer.
    • The drug is a once-daily pill that blocks a protein driving tumor growth.
    • Clinical data indicates the treatment nearly doubles patient survival rates.

    Still unconfirmed

    • RevMed could become the next oncology titan following the Rasonque approval.
    • Questions linger on the ground as RevMed prepares for the drug launch.

    What to watch next

    • Availability and pricing details for RASONQUE
    • Long-term survival data from expanded patient groups
    • Development of similar protein-blocking medicines
    Sources used for this update (14)
    1. The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
    2. Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
    3. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
    4. STAT — Pharmalittle: We're reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
    5. Fierce Pharma — As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
    6. www.forbes.com — Forbes Daily: Nvidia Beats Expectations As Data Center Business Grows
    7. BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
    8. www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
    9. NPR — New FDA-approved drug offers hope in pancreatic cancer treatment : Here & Now Anytime
    10. www.yahoo.com — Groundbreaking pancreatic cancer drug approved by FDA: What we know
    11. www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
    12. www.yahoo.com — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
    confidence 95%

  3. FDA Approves Daraxonrasib for Pancreatic Cancer Treatment

    The FDA has approved daraxonrasib, a once-daily pill designed to treat pancreatic cancer. The drug works by blocking a protein that drives tumor growth in most cases. Clinical data indicates the treatment nearly doubles patient survival rates. This approval introduces a new approach to managing a deadly disease, with some patients, including one with stage 4 cancer in Maine, reporting that the medication is extending their lives.

    Why it matters

    Pancreatic cancer is known as a deadly disease with historically limited treatment options. This drug targets a specific protein fueling tumors in the vast majority of cases. The approval represents a shift in care for patients facing this diagnosis.

    What is confirmed

    • The FDA approved the drug daraxonrasib to treat pancreatic cancer.
    • The medication is a once-daily pill.
    • The drug improves survival rates for patients.

    Still unconfirmed

    • Patient survival rates nearly double with the use of this pill.
    • The drug blocks a protein that fuels tumor growth in the vast majority of cases.
    • A stage 4 cancer patient in Maine says the pill is buying him time.

    What to watch next

    • Publication of full clinical trial data regarding survival rate increases.
    • Insurance coverage and accessibility reports for daraxonrasib.
    Sources used for this update (8)
    1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
    2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
    3. Fox News — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
    4. AP News — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
    5. BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
    6. WGME — Stage 4 Maine cancer patient says new FDA-approved pill is buying him time
    7. CBS News — FDA approves new pancreatic cancer drug that could extend patients' lives
    8. www.boisestatepublicradio.org — FDA approves landmark pancreatic cancer drug that's shown to improve survival
    confidence 90%